Role of 4-hydroxynonenal-protein adducts in human diseases

Antioxidants and Redox Signaling

Volumn 22, Issue 18, 2015, Pages 1681-1702

  Barrera, Giuseppina ^a   Pizzimenti, Stefania ^a   Ciamporcero, Eric Stefano ^a   Daga, Martina ^a   Ullio, Chiara ^a   Arcaro, Alessia ^b   Cetrangolo, Giovanni Paolo ^c   Ferretti, Carlo ^a   Dianzani, Chiara ^a   Lepore, Alessio ^d   Gentile, Fabrizio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; LIPID; PROTEIN; 4-HYDROXY-2-NONENAL; ALDEHYDE;

ATHEROSCLEROSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNITY; BIOCHEMISTRY; CANCER CELL; CELL STRESS; CHEMICAL INTERACTION; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASES; ERYTHROCYTE LIFESPAN; HUMAN; INFLAMMATION; LIPID PEROXIDATION; LIVER TOXICITY; MOLECULAR PATHOLOGY; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; CHEMISTRY; METABOLISM;

ALDEHYDES; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; LIPID PEROXIDATION; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PROTEINS;

EID: 84930613239     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6166     Document Type: Review

References (229)

1. Ait-Oufella H, Taleb S, Mallat Z, and Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31: 969-979, 2011.
2. Akagawa M, Ito S, Toyoda K, Ishii Y, Tatsuda E, Shibata T, Yamaguchi S, Kawai Y, Ishino K, Kishi Y Adachi T, Tsubata T, Takasaki Y, Hattori N, Matsuda T, and Uchida K. Bispecific Abs against modified protein and DNA with oxidized lipids. Proc Natl Acad Sci U S A 103: 6160-6165, 2006.
3. Al-Shobaili HA, Al Robaee AA, Alzolibani AA, and Rasheed Z. Antibodies against 4-hydroxy-2-nonenal modified epitopes recognized chromatin and its oxidized forms: role of vhromatin, oxidized forms of chromatin and 4-hydroxy-2-nonenal modified epitopes on the etiopathogenesis of SLE. Dis Markers 33: 19-34, 2012.
4. Aluise CD, Rose K, Boiani M, Reyzer ML, Manna JD, Tallman K, Porter NA, and Marnett LJ. Peptidyl-prolyl cis/trans-Isomerase A1 (Pin1) is a target for modification by lipid electrophiles. Chem Res Toxicol 26: 270-279, 2013.
5. Amberger A, Maczek C, Jürgens G, Michaelis D, Schett G, Trieb K, Eberl T, indal S, Xu Q, and Wick G. Coexpression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 22: 94-103, 1997.
6. Ando K, Beppu M, and Kitagawa K. Evidence for the accumulation of lipid hydroperoxides during the aging of human red blood cells in the circulation. Biol Pharmacol Bull 18: 659-663, 1995.
7. Andronicos NM, Ranson M, Bognacki J, and Baker MS. The human ENO1 gene product (recombinant human alpha- enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta 1337: 27-39, 1997.
8. Aoyama T, Chen M, Fujiwara H, Masaki T, and Sawamura T. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 467: 217-220, 2000.
9. Arashiki N, Otsuka Y, Ito D, Komatsu T, Sato K, and Inaba M. The covalent modification of spectrin in red cell membranes by the lipid peroxidation product 4-hydroxy- 2-nonenal. Biochem Biophys Res Commun 391: 1543- 1547, 2010.
10. Ashraf MZ, Kar NS, Chen X, Choi J, Salomon RG, Febbraio M, and Podrez EA. Specific oxidized phospholipids inhibit scavenger receptor bi-mediated selective uptake of cholesteryl esters. J Biol Chem 283: 10408-10414, 2008.
11. Awasthi YC, Sharma R, Sharma A, Yadav S, Singhal SS, Chaudhary P, and Awasthi S. Self-regulatory role of 4- hydroxynonenal in signaling for stress induced programmed cell death. Free Radic Biol Med 45: 111-118, 2008.
12. Backos DS, Fritz KS, Roede JR, Petersen DR, and Franklin CC. Post-translational modification and regulation of glutamate cysteine ligase by the a, b-unsaturated aldehyde 4-Hydroxy-2-Nonenal (4-HNE). Free Radic Biol Med 50: 14-26, 2011.
13. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, and Butterfield DA. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52: 2292-2301, 2012.
14. Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012: 137289, 2012.
15. Barrera G, Pizzimenti S, and Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med 29: 1-8, 2008.
16. Berberat PO, Katori M, Kaczmarek E, Anselmo D, Lassman C, Ke B, Shen X, Busuttil RW, Yamashita K, Csizmadia E, Tyagi S, Otterbein LE, Brouard S, Tobiasch E, Bach FH, Kupiec-Weglinski JW, and Soares MP. Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J 17: 1724-1726, 2003.
17. Blanc EM, Kelly JF, Mark RJ, Waeg G, and Mattson MP. 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha(q/11). J Neurochem 69: 570-580, 2007.
18. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Almazan A, Dennis EA, Steinberg D, Witztum JL, and Quehenberger O. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res 46: 969-976, 2005.
19. Bresgen N, Jaksch H, Lacher H, Ohlenschläger I, Uchida K, and Eckl PM. Iron-mediated oxidative stress plays an essential role in ferritin-induced cell death. Free Radic Biol Med. 48: 1347-1357, 2010.
20. Bresgen N, Ohlenschlager I, Fiedler B, Wacht N, Zach S, Dunkelmann B, Arosio P, Kuffner E, Lottspeich F, and Eckl PM. Ferritin - a mediator of apoptosis? J Cell Physiol 212: 157-164, 2007.
21. Bresgen N, Ohlenschlager I, Wacht N, Afazel S, Ladurner G, and Eckl PM. Ferritin and FasL (CD95L) mediate density dependent apoptosis in primary rat hepatocytes. J Cell Physiol 217: 800-808, 2008.
22. Bresgen N, Rolinek R, Hochleitner E, Lottspeich F, and Eckl PM. Induction of apoptosis by a hepatocyte conditioned medium. J Cell Physiol 198: 452-460, 2004.
23. Brown K, Gerstberger S, Carlson L, Franzoso G, and Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267: 1485-1488, 1995.
24. Browne SE and Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 8: 2061-2073, 2006.
25. Bussone G, Dib H, Tamby MC, Broussard C, Federici C, Woimant G, Camoin L, Guillevin L, and Mouthon L. Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor b pathway in patients with systemic sclerosis. Arthritis Res Ther 13: 74, 2011.
26. Butterfield DA, Drake J, Pocernich C, and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548-554, 2001.
27. Butterfield DA, Reed T, and Sultana R. Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic Res 45: 59-72, 2011.
28. Canuto RA, Muzio G, Maggiora M, Biocca ME, and Dianzani MU. Glutathione-S-transferase, alcohol dehydrogenase and aldehyde reductase activities during diethylnitrosamine- carcinogenesis in rat liver. Cancer Lett 68: 177-183, 1993.
29. Casciola-Rosen LA, Anhalt G, and Rosen A. Autoantigens targeted in sistemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317-1330, 1994.
30. Casini A, Galli A, Pignalosa P, Frulloni L, Grappone C, Milani S, Pederzoli P, Cavallini G, and Surrenti C. Collagen type I synthesized by pancreatic periacinar stellate cells (PSC) co-localizes with lipid peroxidation-derived aldehydes in chronic alcoholic pancreatitis. J Pathol 192: 81-89, 2000.
31. Chalasani N, Deeg MA, and Crabb DW. Systemic lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 99: 1497-1502, 2004.
32. Chang NH, MacLeod R, and Wither JE. Autoreactive B cells in lupus-prone New Zealand black mice exhibit aberrant survival and proliferation in the presence of selfantigen in vivo. J Immunol 172: 1553-1560, 2004.
33. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, Kita T, Masaki T, and Sawamura T. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 20: 1107-1115, 2000.
34. Chen M, Kakutani M, Naruka T, Ueda M, Narumiya S, Masaki T, and Sawamura T. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun 282: 153-158, 2001.
35. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, and Li L. Oxidative modifications and downregulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279: 13256-13264, 2004.
36. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, and Li L. Oxidative modifications and aggregation of Cu, Znsuperoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280: 11648-11655, 2005.
37. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI, Chin L-S, and Li L. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281: 10816-10824, 2006.
38. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, Witztum JL, and Binder CJ. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119: 1335-1349, 2009.
39. Cohen G, Riahi Y, and Sasson S. Lipid peroxidation of poly-unsaturated fatty acids in normal and obese adipose tissues. Arch Physiol Biochem 117: 131-139, 2011.
40. Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, and Vanden Heuvel JP. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator- activated receptor-b/d (PPARb/d). Free Radic Biol Med 42: 1155-1164, 2007.
41. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, and Sawamura T. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275: 12633-12638, 2000.
42. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, and Sawamura T. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276: 13750-13755, 2001.
43. Compton CN, Franko AP, Murray MT, Diebel LN, and Dulchavsky SA. Signaling of apoptotic lung injury by lipid hydroperoxides. J Trauma 44: 783-788, 1998.
44. Curzio M, Esterbauer H, DiMauro C, Cecchini G, and Dianzani MU. Chemotactic activity of the lipid peroxidation product 4-hydroxynonenal and homologous hydroxyalkenals and consequences neutrophil motility. Free Rad Res Commun 5: 55-66, 1988.
45. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, and Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet 347: 444-445, 1996.
46. de Sá Oliveira GG, Izui S, Ravirajan CT, Mageed RA, Lydyard PM, Elson CJ, and Barker RN. Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. Clin Exp Immunol 105: 313-320, 1996.
47. Demozay D, Mas JC, Rocchi S, and Van Obberghen E. FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes. Diabetes 57: 1216-1226, 2008.
48. Di Domenico F, Pupo G, Tramutola A, Giorgi A, Schinina ME, Coccia R, Head E, Butterfield DA, and Perluigi M. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med 71C: 270-280, 2014.
49. Dianzani MU. 4-Hydroxynonenal from pathology to physiology. Mol Aspects Med 24: 263-272, 2003.
50. Dix TA and Aikens J. Mechanisms and biological relevance of lipid peroxidation initiation. Chem Res Toxicol 6: 2-18, 1993.
51. Dodson M, Liang Q, Johnson MS, Redmann M, Fineberg N, Darley-Usmar VM, and Zhang J. Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells. Autophagy 9: 1996-2008, 2013.
52. Draude G and Lorenz RL. TGF-beta1 downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages. Am J Physiol Heart Circ Physiol 278: 1042-1048, 2000.
53. Dunn S, Vohra RS, Murphy JE, Homer-Vanniasinkam S, Walker JH, and Ponnambalam S. The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J 409: 349-355, 2008.
54. Eaton P, Li JM, Hearse DJ, and Shattock MJ. Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am J Physiol 276: 935-943, 1999.
55. Emlen W, Niebur J, and Kadera R. Accelerated in vitro apoptosys of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152: 3685-3692, 1994.
56. Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, Horvath L, Wallerskog T, Oukka M, Nyberg F, Kuchroo VK, and Wahren-Herlenius M. The Sjögren's Sydrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176: 6277-6285, 2006.
57. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991.
58. Farzana Khatoon M and Khursheed Alam AA. Physicochemical and immunological studies on 4-hydroxynonenal modified HSA: implications of protein damage by lipid peroxidation products in the etiopathogenesisi of SLE. Hum Immunol 73: 1132-1139, 2012.
59. Flohé SB, Bruggemann J, Lendemans S, Nikulina M, Meierhoff GS, Flohé S, and Kolb H. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 170: 2340-2348, 2003.
60. Fossati-Jimack L, Azeredo da Silveira S, Moll T, Kina T, Kuypers FA, Oldenborg PA, and Reininger L, Izui S. Selective increase of autoimmune epitope expression on aged erythrocytes in mice: implications in anti-erythrocyte autoimmune responses. J Autoimmun 18: 17-25, 2002.
61. Frostegard J, Kjellman B, Gidlund M, Andersson B, Jindal S, and Kiessling R. Induction of a heat-shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis 121: 93-103, 1996.
62. Furukawa F, Itoh T, Wakita H, Yagi H, Tokura Y, Norris DA, and Takigawa M. Keratinocytes form patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol 118: 164-170, 1999.
63. Gan L and Johnson JA. Oxidative damage and the Nrf2- ARE pathway in neurodegenerative diseases. Biochim Biophys Acta 1842: 1208-1218, 2014.
64. Gentile F, Pizzimenti S, Arcaro A, Pettazzoni P, Minelli R, D'Angelo D, Mamone G, Ferranti P, Toaldo C, Cetrangolo G, Formisano S, Dianzani MU, Uchida K, Dianzani C, and Barrera G. Exposure of HL-60 human leukaemic cells to 4-hydroxynonenal promotes the formation of adduct(s) with alpha-enolase devoid of plasminogen binding activity. Biochem J 422: 285-294, 2009.
65. Georgescu L, Vakkalanka RK, Elkon KB, and Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 100: 2622-2633, 1997.
66. Giordano S, Darley-Usmar V, and Zhang J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2: 82-90, 2013.
67. Gómez A and Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87: 1002-1013, 2009.
68. Grundtman C, Kreutmayer SB, Almanzar G, Wick MC, and Wick G. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arterioscler Thromb Vasc Biol 31: 960-968, 2011.
69. Grundtman C and Wick G. The autoimmune concept of atherosclerosis. Curr Opin Lipidol 22: 327-334, 2011.
70. H.s.D.C.R. Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983, 1993.
71. Haberzett P and Hill BG. Oxidized lipids activate autophagy in a JNK-dependent manner by stimulating the endoplasmic reticulum stress response. Redox Biol 1: 56-64, 2013.
72. Hammer A, Ferro M, Tillian HL Tatzber F, Zollner H, Schauenstein E, and Schaur RJ. Effect of oxidative stress by iron on 4-hydroxynonenal formation and proliferative activity in hepatomas of different degrees of differentiation. Free Radic Biol Med 23: 26-33, 1997.
73. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002.
74. Erratum in: Science 297: 2209, 2002.
75. Hashimoto M, Shibata T, Wasada H, Toyokuni S, and Uchida K. Structural basis of protein-bound endogenous aldehydes. Chemical and immunochemical characterization of configurational isomers of a 4-hydroxy-2-nonenalhistidine adduct. J Biol Chem 278: 5044-5051, 2003.
76. Hensley K, Venkova K, Christov A, Gunning W, and Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 43: 180-191, 2011.
77. Herbst U, Toborek M, Kaiser S, Mattson MP, and Hennig B. 4-Hydroxynonenal induces dysfunction and apoptosis of cultured endothelial cells. J Cell Physiol 181: 295-303, 1999.
78. Hill BG, Haberzettl P, Ahmed Y, Srivastava S, and Bhatnagar A. Unsaturated lipid peroxidation-derived aldehydes activate autophagy in vascular smooth-muscle cells. Biochem J 410: 525-534, 2008.
79. Hockenberry DM, Oltvai ZN, Yin X-M, Milliman CL, and Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251, 1993.
80. Hoff HF and O'Neil JA. Modification of LDL with 4- hydroxynonenal and malondialdehyde as a model for soluble oxidized LDL. J Lipid Res 34: 1209-1217, 1993.
81. Hoff HF, O'Neil J, Chisolm GM, Cole TB, Quebenberger O, Esterbauer H, and Jürgens G. Modification of LDL with 4-hydroxynonenal induces uptake of LDL by macrophages. Arteriosclerosis 9: 538-549, 1989.
82. Hoff HF, O'Neil J, Wu Z, Hoppe G, and Salomon RL. Phospholipid hydroxyalkenals. Biological and chemical properties of specific oxidized lipids present in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 23: 275-282, 2003.
83. Huang SC, Scofield RH, Kurien BT, and Harley JB. Human anti-Ro autoantibodies bind multiple conformational epitopes of 60-kD Ro autoantigen. J Clin Immunol 17: 212-219, 1997.
84. Iuchi Y, Kibe N, Tsunoda S, Suzuki S, Mikami T, Okada F, Uchida K, and Fujii J. Implication of oxidative stress as a cause of autoimmune hemolytic anemia in NZB mice. Free Radic Biol Med 48: 935-944, 2010.
85. Iuchi Y, Okada F, Onuma K, Onoda T, Asao H, Kobayashi M, and Fujii J. Elevated oxidative stress in erythrocytes due to an SOD1 deficiency causes anemia and triggers autoantibody production. Biochem J 402: 219-227, 2007.
86. Iuchi Y, Okada F, Takamiya R, Kibe N, Tsunoda S, Nakajima O, Toyoda K, Nagae R, Suematsu M, Soga T, Uchida K, and Fujii J. Rescue of anemia and autoimmune responses in SOD1-deficient mice by transgenic expression of human SOD1 in erythrocytes. Biochem J 422: 313-320, 2009.
87. Ji C, Kozak KR, and Marnett LJ. IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem 276: 18223-18228, 2001.
88. Johri A, Chandra A, and Beal MF. PGC-1a, mitochondrial dysfunction, and Huntington's disease. Free Radic Biol Med 62: 37-46, 2013.
89. Jung KA and Kwak MK. Enhanced 4-hydroxynonenal resistance in KEAP1 silenced human colon cancer cells. Oxid Med Cell Longev 2013: 423965, 2013.
90. Juric-Sekhar G, Zarkovic K, Waeg G, Cipak A, and Zarkovic N. Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. Tumori 95: 762-768, 2009.
91. Kakutani M, Masaki T, and Sawamura T. A plateletendothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci U S A 97: 360-364, 2000.
92. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 274: 27339-27342, 1999.
93. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, and Kita T. Expression of lectin-like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99: 3110-3117, 1999.
94. Kaur K, Salomon RG, O'Neil J, and Hoff HF. (Carboxyalkyl)pyrroles in human plasma and oxidized low-density lipoproteins. Chem Res Toxicol 10: 1387-1396, 1997.
95. Kawamura K, Kobayashi Y, Kageyama F, Kawasaki T, Nagasawa M, Tokoyuni S, Uchida K, and Nakamura I. Enhanced hepatic lipid peroxidation in patients with primary biliary cirrhosis. Am J Gastroenterol 95: 3597-3602, 2000.
96. Khan SA and Vanden Heuvel JP. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids. J Nutr Biochem 14: 554-567, 2003.
97. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, and Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 142: 1927- 1937, 1993.
98. Knoflach M, Bernhard D, and Wick G. Anti-HSP60 immunity is already associated with atherosclerosis early in life. Ann N Y Acad Sci 1051: 323-331, 2005.
99. Knoflach M, Kiechl S, Mayr B, Kind M, Gaston JSH, van der Zee R, Faggionato A, Mayr A, Willeit J, and Wick G. T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis. Atherosclerosis 195: 333-338, 2007.
100. Kristal BS, Park BK, and Yu BP. 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 271: 6033-6038, 1996.
101. Kumano-Kuramochi M, Shimozu Y, Wakita C, Ohnishi- Kameyama M, Shibata T, Matsunaga S, Takano-Ishikawa Y, Watanabe J, Goto M, Xie Q, Komba S, Uchida K, and Machida S. Identification of 4-hydroxy-2-nonenalhistidine adducts that serve as ligands for human lectinlike oxidized LDL receptor-1. Biochem J 442: 171-180, 2012.
102. Kume N, Moriwaki H, Kataoka H, Minami M, Murase T, Sawamura T, Masaki T, and Kita T. Inducible expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth muscle cells. Ann N Y Acad Sci 902: 323-327, 2000.
103. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, and Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277: 49982-49988, 2002.
104. Kurien BT, D'Souza A, Terzyan S, and Scofield RH. Putative sequences on Ro60 three-dimensional structure accessible for 4-hydroxy-2-nonenal (HNE) modification compared to in vitro HNE modification of Ro60 sequences. Mol Immunol 50: 185-192, 2012.
105. Kurien BT, Hensley K, Bachmann M, and Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 41: 549-556, 2006.
106. Kurien T, Porter A, Dorri Y, Iqbal S, D'Souza A, Singh A, Asfa S, Cartellieri M, Mathias K, Matsumoto H, Bachmann M, Hensley K, and Scofield RH. Degree of modification of Ro60 by the lipid peroxidation by-product 4-hydroxy-2-nonenal may differentially induce Sjögren's syndrome or sistemic lupus erythematosus in BALB/c mice. Free Radic Biol Med 50: 1222-1233, 2011.
107. Kurien BT and Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 64: 227-235, 2006.
108. Kurien BT and Scofield RH. Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 44: 349-356, 2006.
109. Kurien BT and Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmunity Rev 7: 567-573, 2008.
110. Lashin OM, Szweda PA, Szweda LI, and Romani AM. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radic Biol Med 40: 886-896, 2006.
111. Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, and Ryu H. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol 121: 487-498, 2011.
112. Lenardo MJ and Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58: 227-229, 1989.
113. Leonarduzzi G, Chiarpotto E, Biasi F, and Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res 49: 1044-1049, 2005.
114. Li CJ, Nanji AA, Siakotos AN, and Lin RC. Acetaldehyde- modified and 4-hydroxynonenal-modified proteins in the livers of rats with alcoholic liver disease. Hepatology 26: 650-657, 1997.
115. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, and Mehta JL. Statins modulate oxidized low-density lipoprotein- mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 302: 601-605, 2002.
116. Li D and Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101: 2889-2895, 2000.
117. Li D and Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 20: 1116-1122, 2000.
118. Licht R, Dieker JWC, Jacobs CWM, Tax WJM, and Berden JHM. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 22: 139-145, 2004.
119. Lin P, Danielson H, and Mannervik B. 4-Hydroxy-2-enals are substrates for glutathione transferase. FEBS Lett 179: 267-270, 1985.
120. Liu W, Akhand AA, Kato M, Yokoyama I, Miyata T, Kurokawa K, Uchida K, and Nakashima I. 4-Hydroxynonenal triggers an epidermal growth factor receptorlinked signal pathway for growth inhibition. J Cell Sci 112: 2409-2417, 1999.
121. Lougheed M, Ming Lum C, Ling W, Suzuki H, Kodama T, and Steinbrecher UP. High-affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/I. J Biol Chem 272: 12938-12944, 1997.
122. Lusis AJ. Atherosclerosis. Nature 407: 233-241, 2000.
123. Mali VR, Ning R, Chen J, Yang XP, Xu J, and Palaniyandi SS. Impairment of aldehyde dehydrogenase-2 by 4-hydroxy-2-nonenal adduct formation and cardiomyocyte hypertrophy in mice fed a high-fat diet and injected with low-dose streptozotocin. Exp Biol Med 239: 610- 618, 2014.
124. Mancuso C and Barone E. The hemeoxygenase/biliverdin reductase pathway in drug research and development. Curr Drug Metab 10: 579-594, 2009.
125. Mandal K, Jahangiri M, and Xu Q. Autoimmunity to heat shock proteins in atherosclerosis. Autoimmun Rev 3: 31-37, 2004.
126. Mark RJ, Pang Z, Geddes JW, Uchida K, and Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17: 1046-1054, 1997.
127. Martínez A, Portero-Otin M, Pamplona R, and Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 20: 281-297, 2010.
128. Matsunaga T, Hokari S, Koyama I, Harada T, and Komoda T. NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun 303: 313-319, 2003.
129. Mielke R, Schroder R, Fink G.R, Kessler J, Herholz K, and Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol 91: 174-179, 1996.
130. Millonig G, Malcom GT, and Wick G. Early inflammatory- immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis 160: 441-448, 2002.
131. Miranda-Carús M-E, Askanase AD, Clancy RM, Di Donato F, Chou T-M, Libera MR, Chan EKL, and Buyon JP. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-a by macrophages. J Immunol 165: 5345-5351, 2000.
132. Monroy CA, Doorn JA, and Roman DL. Modification and functional inhibition of regulator of G-protein signaling 4 (RGS4) by 4-hydroxy-2-nonenal. Chem Res Toxicol 26: 1832-1839, 2013.
133. Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H, Ochi H, Nishi E, Masaki T, and Kita T. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 18: 1541-1547, 1998.
134. Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawamura T, Peckham M, Phillips SE, Walker JH, and Ponnambalam S. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J 393: 107-115, 2006.
135. Nadkarni DV and Sayre LM. Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 8: 284-291, 1995.
136. Negre-Salvayre A, Coatrieux C, Ingueneau C, and Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 153: 6-20, 2008.
137. Nickel T, Schmauss D, Hanssen H, Hanssen H, Sicic Z, Krebs B, Jankl S, Summo C, Fraunberger P, Walli AK, Pfeiler S, and Weis M. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis 205: 442-450, 2009.
138. Nobili V, Parola M, Alisi A, Marra F, Piemonte F, Mombello C, Sutti S, Povero D, Maina V, Novo E, and Albano E. Oxidative stress parameters in paediatric nonalcoholic fatty liver disease. Int J Mol Med 26: 471-476, 2010.
139. Oberley TD, Toyokuni S, and Szweda LI. Localization of hydroxynonenal protein adducts in normal human kidney and selected human kidney cancers. Free Radic Biol Med 27: 695-703, 1999.
140. Ohki I, Ishigaki T, Oyama T, Matsunaga S, Xie Q, Ohnishi- Kameyama M, Murata T, Tsuchiya D, Machida S, Morikawa K, and Tate S. Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 13: 905-917, 2005.
141. Oka K, Sawamura T, Kikuta K, Itokawa S, Kume N, Kita T, and Masaki T. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci U S A 95: 9535-9540, 1998.
142. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, Bu G, Banks WA, and Butterfield DA. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Ab accumulation in AD brain. Free Radic Biol Med 49: 1798-1803, 2010.
143. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, and Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10: 325-335, 1990.
144. Pan Z-J, Davis K, Maier S, Bachmann MP, Kim-Howard XR, Keech C, Gordon TP, McCluskey J, and Farris AD. Neo-epitopes are required for immunogenicity of La/SS-B nuclear antigen in the context of late apoptotic cells. Clin Exp Immunol 143: 237-248, 2006.
145. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 58: 902-920, 2001.
146. Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra- Bilen J, and Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res 106: 383-390, 2010.
147. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, and Mattson MP. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 44: 819-824, 1998.
148. Perluigi M and Butterfield DA. Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr Gerontol Geriatr Res 2012: 724904, 2012.
149. Perluigi M, Fai Poon H, Hensley K, Pierce WM, Klein JB, Calabrese V, De Marco C, and Butterfield DA. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 38: 960-968, 2005.
150. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, and Butterfield DA. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3: 682-693, 2009.
151. Petersen DR and Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 37: 937-945, 2004.
152. Pettazzoni P, Ciamporcero E, Medana C, Pizzimenti S, Dal Bello F, Minero VG, Toaldo C, Minelli R, Uchida K, Dianzani MU, Pili R, and Barrera G. Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radic Biol Med 51: 1610-1618, 2011.
153. Pizzimenti S, Ciamporcero E, Daga M, Pettazzoni P, Arcaro A, Cetrangolo G, Minelli R, Dianzani C, Lepore A, Gentile F, and Barrera G. Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Front Physiol 4: 242, eCollection, 2013.
154. Pizzimenti S, Laurora S, Briatore F, Ferretti C, Dianzani MU, and Barrera G. Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic Biol Med 32: 233-245, 2002.
155. Pizzimenti S, Toaldo C, Pettazzoni P, Dianzani MU, and Barrera G. The "Two-Faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. Cancers 2: 338- 363, 2010.
156. Player TJ, Mills DJ, and Horton AA. Lipid peroxidation of the microsomal fraction and extracted microsomal lipids from DAB-induced hepatomas. Br J Cancer 39: 773-778, 1979.
157. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, and Sun M. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277: 38517-38523, 2002.
158. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, and Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277: 38503-38516, 2002.
159. Poon HF, Calabrese V, Scapagnini G, and Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A Biol Sci Med Sci 59: 478-493, 2004.
160. Pryor WA and Porter NA. Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. Free Radic Biol Med 8: 541-543, 1990.
161. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, and Fink AL. Effect of 4-hydroxy-2-nonenal modification on alphasynuclein aggregation. J Biol Chem 282: 5862-5870, 2007.
162. Quach TT, Duchemin AM, Rogemond V, Aguera M, Honnorat J, Belin MF, and Kolattukudy PE. Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. Mol Cell Neurosci 25: 433-443, 2004.
163. Rahajeng J, Giridharan SS, Naslavsky N, and Caplan S. Collapsin response mediator protein-2 (Crmp2) regulates trafficking by linking endocytic regulatory proteins to dynein motors. J Biol Chem 285: 31918-31922, 2010.
164. Recalcati S, Invernizzi P, Arosio P, and Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 30: 84-89, 2008.
165. Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 51: 1302-1319, 2011.
166. Ren Y, Tang J, Mok MY, Chan AW, Wu A, and Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48: 2888-2897, 2003.
167. Rossi MA and Cecchini G. Lipid peroxidation in hepatomas of different degrees of deviation. Cell Biochem Funct 1: 49-54, 1983.
168. Rossmann A, Henderson B, Heidecker B, Seiler R, Fraedrich G, Singh M, Parson W, Keller M, Grubeck- Loebenstein B, and Wick G. T-cells from advanced atherosclerotic lesions recognize hHSP60 and have a restricted T-cell receptor repertoire. Exp Gerontol 43: 229-237, 2008.
169. Sajdel-Sulkowska EM and Marotta CA. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease- inhibitor complex. Science 225: 947-949, 1984.
170. Salomon RG and Gu X. Critical insights into cardiovascular disease from basic research on the oxidation of phospholipids: the c-hydroxyalkenal phospholipid hypothesis. Chem Res Toxicol 24: 1791-1802, 2011.
171. Salomon RG, Kaur K, Podrez E, Hoff HF, Krushinsky AV, and Sayre LM. HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol: 557-564, 2000.
172. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
173. Sanders LH and Greenamyre JT. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med 62: 111-120, 2013.
174. Savill J, Dransfield I., Gregory C, and Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2: 965-975, 2002.
175. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, and Masaki T. An endothelial receptor for oxidized lowdensity lipoprotein. Nature 386: 73-77, 1997.
176. Schägger H and Ohm TG. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur J Biochem 227: 916-921, 1995.
177. Scheff SW, Price DA, Schmitt FA, Scheff MA, and Mufson EJ. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 24: 547-557, 2011.
178. Scofield RH, Kurien BT, Ganick S, McClain MT, Pye Q, James JA, Schneider RI, Broyles RH, Bachmann M, and Hensley K. Modification of lupus-associated 60- kDa Ro protein with the lipid oxidation product 4- hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading. Free Radic Biol Med 38: 719-728, 2005.
179. Scofield RH, Kurien BT, and Reichlin M. Immunologically restricted and inhibitory anti-Ro/SSA in monozygotic twins. Lupus 6: 395-398, 1997.
180. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, and Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 37: 56-62, 2002.
181. Sellin S, Holmquist B, Mannervik B, and Vallee BL. Oxidation and reduction of 4-hydroxyalkenals catalyzed by isozymes of human alcohol dehydrogenase. Biochemistry 30: 2514-2518, 1991.
182. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, and Naoi M. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114: 1559-1567, 2007.
183. Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, and Niki E. a-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med 50: 1801-1811, 2011.
184. Shimaoka T, Kume N, Minami M, Hayashida K, Sawamura T, Kita T, and Yonehara S. LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol 166: 5108-5114, 2001.
185. Siegel SJ, Bieschke J, Powers ET, and Kelly JW. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46: 1503-1510, 2007.
186. Smirnova IV, Kajstura M, Sawamura T, and Goligorsky MS. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 287: 782-790, 2004.
187. Starzyński RR, Canonne-Hergaux F, Willemetz A, Gralak MA, Woliński J, Stys̈ A, Olszak J, and Lipiński P. Hemolytic anemia and alterations in hepatic iron metabolism in aged mice lacking Cu, Zn-superoxide dismutase. Biochem J 420: 383-390, 2009.
188. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol 369: 39-48, 1995.
189. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Wittztum JL. Beyond cholesterol: modifications of lowdensity lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989.
190. Steinbrecher UP. Receptors for oxidized low density lipoprotein. Biochim Biophys Acta 1436: 279-298, 1999.
191. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, and Butterfield DA. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11: 153-164, 2007.
192. Sultana R, Perluigi M, and Butterfield AD. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med 62: 157-169, 2013.
193. Sun J, Hartvigsen K, Chou MY, Zhang Y, Sukhova GK, Zhang J, Lopez-Ilasaca M, Diehl CJ, Yakov N, Harats D, George J, Witztum JL, Libby P, Ploegh H, and Shi GP. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation 122: 808-820, 2010.
194. Sun M, Deng Y, Batyreva E, Sha W, and Salomon RG. Novel bioactive phospholipids: practical total syntheses of products from the oxidation of arachidonic and linoleic esters of 2-lysophosphatidylcholine. J Biol Chem 67: 3575-3584, 2002.
195. Sutti S, Jindal A, Vacchiano M, Gigliotti L, Bozzola C, and Albano E. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 59: 886-897, 2014.
196. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira Tde A, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, and Diehl AM. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61: 1323-1329, 2012.
197. Tamamizu-Kato S, Wong JY, Jairam V, and Uchida K. Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E. Biochemistry 46: 8392-8400, 2007.
198. Tjalkens RB, Cook LW, and Petersen DR. Formation and export of the glutathione conjugate of 4-hydroxy-2, 3-Enonenal (4-HNE) in hepatoma cells. Arch Biochem Biophys 361: 113-119, 1999.
199. Toyoda K, Nagae R, Akagawa M, Ishino K, Shibata T, Ito S, Shibata N, Yamamoto T, Kobayashi M, Takasaki Y, Matsuda T, and Uchida K. Protein-bound 4-hydroxy-2- nonenal. An endogenous triggering antigen of anti-DNA response. J Biol Chem 282: 25769-25778, 2007.
200. Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
201. Traverso N, Menini S, Odetti P, Pronzato MA, Cottalasso D, and Marinari UM. Lipoperoxidation in hepatic subcellular compartments of diabetic rats. Free Radic Biol Med 26: 538-547, 1999.
202. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42: 318-343, 2003.
203. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S, and Stadtman ER. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 324: 241-248, 1995.
204. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, and Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 95: 4882-4887, 1998.
205. Uchida K, Sakai K, Itakura K, Osawa T, and Toyokuni S. Protein modification by lipid peroxidation products: formation of malondialdehyde-derived Ne-(2-propenal)lysine in proteins. Arch Biochem Biophys 346: 45-52, 1997.
206. Usatyuk PV and Natarajan V. Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc Res 83: 45-55, 2012.
207. van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, and Stalenhoef AF. Oxidized LDL enhances proinflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 214: 345-349, 2011.
208. Vanden Heuvel JP. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci 47: 1-8, 1999.
209. Vohra RS, Murphy JE, Walker JH, Ponnambalam S, and Homer-Vanniasinkam S. Atherosclerosis and the lectinlike oxidized low-density lipoprotein scavenger receptor. Trends Cardiovasc Med 16: 60-64, 2006.
210. Wagner TM, Mullally JE, and Fitzpatrick FA. Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4- hydroxy-2-nonenal covalently modify and inhibit the ampkinase kinase thatmodulates cellular energy homeostasis and protein translation. J Biol Chem 281: 2598-2604, 2006.
211. Wang G, Pierangeli SS, Papalardo E, Ansari GAS, and Khan F. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 62: 2064-2072, 2010.
212. Wang Z, Dou X, Gu D, Shen C, Yao T, Nguyen V, Braunschweig C, and Song Z. 4-hydroxynonenal differentially regulates adiponectin gene expression and secretion via activating PPAR and accelerating ubiquitin-proteasome degradation. Mol Cell Endocrinol 349: 222-231, 2012.
213. Watanabe K, Nakazato Y, Saiki R, Igarashi K, Kitada M, and Ishii I. Acrolein-conjugated low-density lipoprotein induces macrophage foam cell formation. Atherosclerosis 227: 51-57, 2013.
214. Weismann D and Binder CJ. The innate immune response to products of phospholipid peroxidation. Biochim Biophys Acta 1818: 2465-2475, 2012.
215. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: 413-422, 2002.
216. Whitman S, GezginciM, Timmermann BN, and Holman TR. Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. J Med Chem 45: 2659-2661, 2002.
217. Winter CK, Segall HJ, and Haddon WF. Formation of cyclic adducts of deoxyguanosine with the aldehydes trans-4-hydroxy-2-hexenal and trans-4-hydroxy-2-nonenal in vitro. Cancer Res 46: 5682-5686, 1986.
218. Wuttge DM, Bruzelius M, and Stemme S. T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology 98: 273-279, 1999.
219. Xie J, Zhu H, Guo L, Ruan Y, Wang L, Sun L, Zhou L, Wu W, Yun X, Shen A, and Gu J. Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein-60 fused antigen into the MHC class I presentation pathway. J Immunol 185: 2306-2313, 2010.
220. Xu G, Liu Y, Kansal MM, and Sayre LM. Rapid crosslinking of proteins by 4-ketoaldehydes and 4-hydroxy- 2-alkenals does not arise from the lysine-derived monoalkylpyrroles. Chem Res Toxicol 12: 855-861, 1999.
221. Xu QB, Oberhuber G, Gruschwitz M, and Wick G. Immunology of atherosclerosis cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopathol 56: 344-359, 1990.
222. Yamada S, Kumazawa S, Ishii T, Nakayama T, Itakura K, Shibata N, Konayashi M, Sakai K, Osawa T, and Uchida K. Immunochemical detection of a lipofuscin-like fluorophore derived from malondialdehyde and lysine. J Lipid Res 42: 1187-1196, 2001.
223. Yao PL, Morales JL, Zhu B, Kang BH, Gonzalez FJ, and Peters JM. Activation of peroxisome proliferator-activated receptor-b/d (PPAR-b/d) inhibits human breast cancer cell line tumorigenicity. Mol Cancer Ther 13: 1008- 1017, 2014.
224. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, and Mizuno Y. Immunohistochemical detection of 4- hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93: 2696-2701, 1996.
225. Yoshida H, Kondratenko N, Green S, Steinberg D, and Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J 334: 9-13, 1998.
226. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M, and Parola M. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 40: 60-68, 2004.
227. Zandman-Goddard G and Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 6: 457-463, 2007.
228. Zeher M, Szodoray P, Gyimesi E, and Szondy Z. Correlation of increased susceptibility to apoptosis of CD4+ T cells with lymphocyte activation and activity of disease in patients with primary Sjögren's syndrome. Arthritis Rheum 42: 1673-1681, 1999.
229. Zhao G, Arosio P, and Chasteen ND. Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study. Biochemistry 45: 3429-3436, 2006.